Wall Street brokerages expect Dova Pharmaceuticals Inc (NASDAQ:DOVA) to announce $4.79 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Dova Pharmaceuticals’ earnings, with estimates ranging from $4.00 million to $5.67 million. The business is scheduled to report its next earnings results on Thursday, February 21st.

On average, analysts expect that Dova Pharmaceuticals will report full-year sales of $12.18 million for the current financial year, with estimates ranging from $11.00 million to $13.18 million. For the next fiscal year, analysts expect that the firm will report sales of $58.85 million, with estimates ranging from $41.00 million to $74.92 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Dova Pharmaceuticals.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.12. The company had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $2.66 million.

Several equities analysts have recently issued reports on the company. BidaskClub raised Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 31st. Raymond James assumed coverage on Dova Pharmaceuticals in a research report on Wednesday, August 29th. They issued an “outperform” rating and a $44.00 price target for the company. Leerink Swann lowered their price target on Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating for the company in a research report on Tuesday, September 4th. Finally, Zacks Investment Research raised Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. Dova Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $33.20.

Shares of DOVA traded up $0.06 during trading hours on Monday, hitting $14.48. The company had a trading volume of 151,289 shares, compared to its average volume of 176,013. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.50 and a quick ratio of 7.40. The firm has a market cap of $406.70 million, a PE ratio of -10.34 and a beta of 0.71. Dova Pharmaceuticals has a 52-week low of $14.09 and a 52-week high of $37.00.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DOVA. Vanguard Group Inc. grew its position in Dova Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock valued at $12,993,000 after acquiring an additional 14,985 shares during the last quarter. Teachers Advisors LLC grew its position in Dova Pharmaceuticals by 19.8% in the 3rd quarter. Teachers Advisors LLC now owns 21,561 shares of the company’s stock valued at $452,000 after acquiring an additional 3,556 shares during the last quarter. Nexthera Capital LP grew its position in Dova Pharmaceuticals by 25.2% in the 3rd quarter. Nexthera Capital LP now owns 1,026,906 shares of the company’s stock valued at $21,534,000 after acquiring an additional 206,558 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Dova Pharmaceuticals in the 3rd quarter valued at $2,516,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Dova Pharmaceuticals in the 3rd quarter valued at $242,000. Institutional investors own 37.14% of the company’s stock.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

See Also: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.